This list is an analysis based on recent market events. It's not an investment recommendation.
About
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Show more...
CEO
Stephen Dilly
Employees
69
Country
US
ISIN
US82640U4040
Listings
0 Comments
Share your thoughts
FAQ
What is Sierra Oncology stock price today?▼
The current price of SRRA is $54.99 USD — it has increased by +0.04% in the past 24 hours. Watch Sierra Oncology stock price performance more closely on the chart.
What is Sierra Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sierra Oncology stocks are traded under the ticker SRRA.
What is Sierra Oncology market cap?▼
Today Sierra Oncology has the market capitalization of 690.71M
How many employees does Sierra Oncology have?▼
As of April 05, 2026, the company has 69 employees.
In which sector is Sierra Oncology located?▼
Sierra Oncology operates in the Manufacturing sector.
When did Sierra Oncology complete a stock split?▼
The last stock split for Sierra Oncology was on January 23, 2020 with a ratio of 1:40.
Where is Sierra Oncology headquartered?▼
Sierra Oncology is headquartered in Vancouver, US.